Home -> Law Blog Directory -> Criminal Law Blogs -> Crime and Consequences
OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Criminal Law
: Crime and ConsequencesOregon Initiatives
By Kent Scheidegger et al.
ADVERTISEMENTS
Oregon votes approved by a 61-39 vote Ballot Measure No. 57: "Increases sentences for drug trafficking, theft against elderly and specified repeat property and identity theft crimes; requires addiction treatment for certain offenders." Final tally here. Info page with link to full text here. An editorial by the Oregonian is here.
SL&P points us to this post at Drug War Chronicle bemoaning the passage of both Measures 57 and 61. They appear to be mistaken. Both the Oregonian editorial and the Secretary of State page linked above indicate that 61 was narrowly defeated.Full post as published by Crime and Consequences on November 07, 2008 (boomark / email).
Lawsuits and Settlements
Understaffed Elder Care
Sunwest Management pays $5.5 million in two class action settlements with California and Oregon residents.
Matrixx Initiatives Inc.,
401(k) / ERISA Stock Fraud
Related Searches
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.

Dueling Oregon initiatives on drug sentencing reform
More on the fate of drug sentencing reform initiatives in the states
New L&C Law Scholarship: Environmental Justice in Oregon
Opponents of Oregon gay rights law abandon repeal effort
Oregon Supreme Court issues opinions on pro-family ballot titles
GAO Report on FDA: Recent Initiatives Have Potential But Weaknesses Remain









